RxDoctor Payments Data

Stacy Congdon

Family · Johnson City, NYNPI 1265661490

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 88 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$293
  • Novo Nordisk$211
  • Abbott$199
  • Inspire Medical Systems, Inc.$106
  • Dexcom, Inc.$102
  • Tandem Diabetes Care, Inc.$100
  • plus $865 from 23 others

What the payments were for

  • Food & beverage$1,876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,876 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$40,408
Medicare patients
215
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide652$1,235,004
MounjaroTirzepatide421$480,008
JardianceEmpagliflozin231$354,728
TrulicityDulaglutide221$334,893
Tresiba Flextouch U-200Insulin Degludec154$315,968
FarxigaDapagliflozin Propanediol168$233,373
Tresiba Flextouch U-100Insulin Degludec183$166,612
Humalog Kwikpen U-100Insulin Lispro293$166,543
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7165$137,125
Novolog FlexpenInsulin Aspart273$131,051
JanuviaSitagliptin Phosphate87$129,317
Lantus SolostarInsulin Glargine,hum.Rec.Anlog492$99,251
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog140$98,997
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog59$86,986
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt42$81,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$211$1,319,010756 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$293$839,660712 claims
Boehringer IngelheimJardiance, Tradjenta$52$429,232298 claims
Sanofi-aventis U.S. LLCLantus$63$7,48725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →